# ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)

> **NCT01218971** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 332 (actual)

## Conditions studied

- Alcohol Dependence

## Interventions

- **DRUG:** Medisorb naltrexone 190 mg
- **DRUG:** Medisorb naltrexone 380 mg

## Key facts

- **NCT ID:** NCT01218971
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2010-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218971, "ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01218971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*